Core Viewpoint - Mingde Biological (002932) is expected to face a significant loss in 2025, with a projected total profit loss of 50 million to 75 million yuan and a net profit loss attributable to shareholders of 15 million to 25 million yuan, leading to a potential delisting risk warning from the Shenzhen Stock Exchange [1][2]. Financial Performance Summary - The revised total profit for 2025 is projected to be a loss of 50 million to 75 million yuan, compared to a profit of 32.416 million yuan in the previous year [2]. - The net profit attributable to shareholders is now expected to be a loss of 15 million to 25 million yuan, revised from a previous estimate of a profit of 12 million to 18 million yuan [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 100 million to 140 million yuan, indicating a significant downward revision [2][3]. - The expected operating revenue for 2025 is estimated to be between 25 million and 31 million yuan, down from 350.0618 million yuan in the previous year [2]. - The adjusted operating revenue, after deductions, is projected to be between 23.7 million and 29.7 million yuan, also a decrease from 348.4858 million yuan in the previous year [2]. Reasons for Performance Revision - The company conducted a comprehensive review and cautious analysis of its operating revenue, deciding not to recognize certain revenues due to significant uncertainty regarding accounts receivable collections [3]. - Further communication with the annual audit accounting firm led to impairment testing of assets showing signs of impairment, resulting in adjustments to asset impairment loss amounts, which negatively impacted the net profit attributable to shareholders [4]. Company Operations Status - The company stated that its production and operations are currently normal and expressed sincere apologies for any inconvenience caused to investors by the performance forecast revision [5].

Core Viewpoint - Shandong Keyuan Pharmaceutical Co., Ltd. has significantly revised its 2025 profit forecast, expecting a net profit decline of 70%-80% due to an unexpected legal dispute involving its subsidiary [1][2] Group 1: Profit Forecast Revision - The company revised its expected net profit from a previous estimate of 27.20 million to 39.29 million yuan (a decline of 35%-55%) to a new range of 12.09 million to 18.13 million yuan (a decline of 70%-80%) [1][2] - The legal dispute involves a compensation of 16.11 million yuan that will be recognized as an extraordinary expense, impacting the net profit [1][2] Group 2: Legal and Financial Implications - The subsidiary, Shandong Linuo Pharmaceutical Co., Ltd., has had some bank accounts frozen due to the legal dispute, with 57 million yuan frozen, representing 4.19% of the company's latest audited net assets [2] - The ongoing legal issues have the potential to affect the normal operations of the subsidiary [2] Group 3: Historical Performance and Challenges - In 2023, the company reported a revenue of 448 million yuan, a slight increase of 1.07%, but net profit decreased by 15.60% to 77.04 million yuan [2] - For 2024, revenue grew by 3.60% to 464 million yuan, but net profit fell to 60.45 million yuan, a decline of 21.54% [2] - The first three quarters of 2025 showed continued deterioration, with revenue at 303 million yuan (down 8.5%) and net profit at 31.47 million yuan (down 20.7%) [2] Group 4: Strategic Moves and Acquisitions - The company attempted to find new growth through acquisitions, planning to acquire 99.42% of Hongjitang for up to 3.581 billion yuan, which was seen as a significant asset restructuring [3][4] - The acquisition was expected to enhance the company's business by integrating traditional Chinese medicine with chemical pharmaceuticals, aiming for cost reduction and improved operational efficiency [4] Group 5: Termination of Acquisition - On November 28, the company decided to terminate the acquisition due to changes in the overall market environment, which were not elaborated upon [5] - The acquisition price was deemed excessively high, equating to 7.7 times the company's 2024 revenue and 59 times its net profit, far exceeding its capital capacity [5]

Core Viewpoint - The company Koyuan Pharmaceutical (301281) has significantly revised its net profit forecast for 2025, expecting a decline of 70% to 80% compared to the previous year due to a lawsuit involving its subsidiary, Lino Pharmaceutical. Financial Performance - The revised forecast for net profit attributable to shareholders is between 12.09 million yuan and 18.13 million yuan, down from the previous estimate of 27.20 million yuan to 39.29 million yuan, which represented a decline of 35% to 55% year-on-year [1][2] - The non-recurring net profit remains unchanged at between 20.12 million yuan and 29.06 million yuan [1][2] Legal Issues - Lino Pharmaceutical received a civil judgment from the Jiangsu Province court, requiring it to pay 16.11 million yuan in compensation related to a contract dispute with Jiangsu Saibang Pharmaceutical [1][3] - This judgment is considered an event that requires adjustment to the financial statements, leading to an increase in non-operating expenses by approximately 16.11 million yuan, which will reduce the net profit attributable to shareholders [3] Operational Challenges - Due to the contract dispute, one of Lino Pharmaceutical's bank accounts has been frozen, with 57 million yuan in funds affected, representing 4.19% of the company's latest audited net assets attributable to shareholders [6] - Koyuan Pharmaceutical primarily engages in the research, production, and sales of chemical raw materials and their formulations, along with intermediate business [6] Market Activity - In November 2025, Koyuan Pharmaceutical announced the termination of its acquisition of Hongjitang, initially planned to purchase 99.42% of the shares from Lino Investment Holding Group and others [6] - The decision to terminate the acquisition was made after careful consideration of changes in the overall market environment, aiming to protect the long-term interests of all shareholders [6]

Core Viewpoint - Aojing Medical Technology Co., Ltd. has revised its 2024 performance forecast, indicating a decline in revenue and net profit compared to the previous year [1][2] Financial Performance Summary - The corrected total operating revenue for 2024 is 206.03 million yuan, a decrease of 9.03% year-on-year [1] - The net profit attributable to shareholders of the parent company is -12.66 million yuan, a decline of 123.35% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is -28.37 million yuan, a decrease of 210.11% year-on-year [1] - The corrected operating profit is -7.36 million yuan, an increase of 48.79% compared to the previous forecast [1] - The corrected total profit is -0.90 million yuan, an increase of 44.29% compared to the previous forecast [1] - The corrected basic earnings per share is -0.09 yuan, an increase of 30.76% compared to the previous forecast [1] Reasons for Correction - The correction is primarily due to adjustments in share-based payment amounts following the determination of the number of participants in the second phase of restricted stock [2] - The adjustments have led to increases in total profit, net profit attributable to shareholders, net profit after deducting non-recurring gains and losses, basic earnings per share, and other financial metrics [2] - The company has expressed apologies for any inconvenience caused to investors and emphasized the importance of careful judgment and communication with auditors in future financial reporting [2]

Core Viewpoint - Keda Guokuan (科大国创) has significantly revised its 2024 performance forecast downward, now expecting a net loss of 5 to 10 million yuan, compared to the previous profit estimate of 22 to 33 million yuan [1][2] Group 1: Performance Revision - The company initially projected a net profit of 22 to 33 million yuan for 2024, reversing from a loss of 380 million yuan in the previous year [1] - The revised forecast indicates a net loss of 5 to 10 million yuan and a non-recurring loss of 42 to 47 million yuan [1][2] - The revision is attributed to overdue accounts receivable from certain clients and unexpected litigation, leading to a reassessment of the recoverability of these receivables [1][2] Group 2: Business Operations and Legal Issues - The issues stem from the company's digital logistics supply chain business, where overdue accounts and litigation have arisen [2] - As of April 7, the company reported a total of 230 million yuan in litigation and arbitration cases, accounting for 12.26% of its latest audited net assets [2] - The company has been actively pursuing legal action to recover overdue payments, with a total of 9630.13 million yuan in impairment provisions for accounts receivable recorded in the first three quarters of 2024 [3]